Who are Metalyse's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Activase, Trasylol, Cyklokapron, Amicar, Recombinant Streptokinase, IV TXA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metalyse.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Metalyse — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metalyse (Metalyse) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Other.

phase 3 Plasminogen Other Biologic Live · refreshed every 30 min

Target snapshot

Metalyse (Metalyse) — AO GENERIUM.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Metalyse TARGET	Metalyse	AO GENERIUM	phase 3		Plasminogen
Activase	ALTEPLASE	Roche	marketed		Plasminogen	1996-01-01
Trasylol	APROTININ	Bayer	marketed	Antifibrinolytic Agent	Plasminogen	1993-01-01
Cyklokapron	TRANEXAMIC ACID	Exela Pharma	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1986-01-01
Amicar	AMINOCAPROIC ACID	Epic Pharma Llc	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1964-01-01
Recombinant Streptokinase	Recombinant Streptokinase	Beijing Chao Yang Hospital	marketed	Fibrinolytic agent / Thrombolytic	Plasminogen
IV TXA	IV TXA	Massachusetts General Hospital	marketed	Antifibrinolytic agent	Plasminogen / Plasmin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Metalyse — Competitive Intelligence Brief. https://druglandscape.com/ci/metalyse. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing